The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 12, 2012, Pages 1175-1187

  Simão, Andréa Name Colado ^a,b   Lozovoy, Marcell Alysson Batisti ^b,c   Dichi, Isaias ^a  

^a UNIVERSITY OF LONDRINA   (Brazil)

^b University of North Paraná ^*  (Brazil)

^c UNIVERSIDADE NORTE DO PARANÁ   (Brazil)

Author keywords

Inflammation; Insulin resistance; Metabolic syndrome; Oxidative stress; Uric acid

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FENOFIBRATE; FRUCTOSE; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; LOSARTAN; METFORMIN; SALICYLIC ACID DERIVATIVE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; URIC ACID;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; COMORBIDITY; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; HYPERURICEMIA; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORTALITY; NONHUMAN; OBESITY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; REVIEW;

EID: 84869460891     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.723694     Document Type: Review

References (104)

1. Kylin E. [Studies of the hypertension-hyperglycemia-hyperuricemia syndrome] Studien uber das Hypertonie-Hyperglykamie-hyperurikamiesyndrome. Zentralbl Innere Med 1923;44:105-27
2. Zavaroni I, Mazza S, Fantuzzi M, et al. Changes in insulin and lipid metabolism in males with asymptomatic hypeuricaemia. J Intern Med 1993;234:25-30
3. Gercsh C, Palii SP, Kim KM, et al. Inactivation of nitric oxide by UA. Nucleosides Nucleotides Nucleic Acids 2008;27:967-78
4. Mazzali M, Hughes J, Kim YG, et al. Elevated UA increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6
5. George J, Stuthers AD. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag 2009;5:265-72
6. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Inter Med 2004;143:499-516
7. Sanchez-Lozada LG, Nakagawa T, Kang D-H, et al. Herrera-Acosta, J. Hormonal and cytokine effects of UA. Curr Opin Nephrol Hypertens 2006;15:30-3
8. Facchini F, Chen I, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary UA clearance, and plasma uric concentration. JAMA 1991;266:3008-11
9. Sundstrom J, Sullivan L, D'Agostino RB, et al. Relations of serum UA to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005;45:28-33
10. Alper AB Jr, Chen WC, Yau L, et al. Childhood UA predicts adult blood pressure. The Bogalusa Heart Study. Hypertension 2005;45:34-8
11. Choi HK, Ford ES. Prevalence of the MS in individuals with hyperuricemia. Am J Med 2007;120:442-7
12. Lin KC, Tsao HM, Chen CH, Chou P. Hypertension was the major risk factor leading to development of cardiovascular diseases among men with hyperuricemia. J Rheumatol 2004;31:1152-8
13. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Intern 2005;67:1739-42
14. Tomita M, Mizuno S, Yamanaka H, et al. Does hypeuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000;10:403-9
15. Ames BN, Cathcart R, Schwiers E, Hochstein P. UA provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78:6858-62
16. Simao ANC, Dichi JB, Barbosa DS, et al. Influence of UA and gamma-glutamyltransferase on total antioxidant capacity and oxidative stress in patients with MS. Nutrition 2008;24:675-81
17. Koprovski H, Spitsin SV, Hooper DC. Prospects for the treatment of multiple sclerosis by raising serum levels of UA, a scavenger of peroxynitrite. Ann Neurol 2001;49:139
18. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant UA in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress Am J Physiol Cell Physiol. 2007;293:C584-96
19. Halliwell B, Gutteridge JMC. Antioxidant protection by compounds synthesized in vivo. 3rd edition. Oxford University Press; New York:1999. p. 19-197
20. Nieto FJ, Iribarren C, Gross MD, et al. UA and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000;148:131-9
21. Molnar D, Decsil T, Koletzko B. Reduced antioxidant status in obese children with multiMS. Intern J Obesity 2004;28:1197-202
22. Sautin YY, Johnson RJ. UA: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008;27:608-19
23. George J, Struthers A. The role of urate and xanthine oxidase in vascular oxidative stress: future directions. Therap Clinic Risk Manag 2009;5:799-803
24. Imaram W, Gersch C, Kim KM, et al. Radicals in the reaction between peroxynitrite and UA identified by electron spin resonance spectroscopy and liquid chromatography mass spectrometry. Free Radic Biol Med 2010;49:275-81
25. Cecchini R, Aruoma OI, Halliwell B. The action of hydrogen peroxide on the formation of thiobarbitUA-reactive material from microsomes or from DNA damage by bleomycin or o-phenanthroline. Artefacts in the thiobarbit UA test. Free Rad Res Commun 1990;10:245-58
26. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with UA n the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 2005;70:343-54
27. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discovery 2007;6:662-80
28. Augusto O, Bonini MG, Amanso AM, et al. Nitrogen dioxide and carbonate radical anion: two emerging radicals in biology. Free Radic Biol. Med 2002;32:841-59
29. Yiginer O, Ozcelik F, Inanc T, et al. Allopurinol improves endothelial function and reduces oxidnt-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol 2008;97:334-40
30. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering UA. Circulation 2006;114:2508-16
31. Maxwell SR, Thomason H, Sandler D, et al. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997;27:484-90
32. Hayden MR, Tyagi SC. UA: A new look at an old risk marker for cardiovascular disease, MS, and the diabetes mellitus: the urate redox shuttle. Nutr Metab 2004;1:1-10
33. Cannon PJ, Stason WB, Demartini FE, et al. Hypeuricemia in primary and renal hypertension. N Engl J Med 1966;275:457-64
34. Johnson RJ, Feig DI, Herrera-Acosta J, Kang D-H. Resurrection of UA as a causal risk factor in essential hypertension. Hypertension 2005;45:18-20
35. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the IR syndrome in young black and white adults: the CARDIA study. Ann Epidemiol 1998;8:250-61
36. Feig DI, Kang DH, Johnson RJ. UA and cardiovascular disease. NEJM 2008;359:1811-21
37. Hovind P, Rossing P, Tarnow L, et al. Serum acid uric as a predictor for development of diabetic nephropathy in type 1 diabetes. Diabetes 2009;58:1668-71
38. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum UA concentration and IR and MS. Cir J 2005;69:928-33
39. Mene P, Punzo G. UA: bystander or culprit in hypertension and progressive renal disease? J Hypertens 2008;26:2085-92
40. Gagliardi ACM, Miname MH, Santos RD. UA: a marker of increased cardiovascular risk. Atherosclerosis 2009;202:11-17
41. Kanellis J, Kang DH. UA as a mediator of endothelial dysfunction, inflammation, and vascular disease. Sem Nephrol 2005;25:39-43
42. Choi JW, Ford ES, Gao X, Choi HK. Sugar sweetened soft drinks, diet soft drinks, and serum acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008;59:109-16
43. Nakagawa T, Hu H, Zharikov S, et al. A causal role for UA in fructose-induced MS. Am J Physiol Renal Physiol 2006;290:F625-31
44. Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cadiol 2004;94:932-5
45. Ho W-J, Tsai W-P, Yu K-H, et al. Association between endothelial function and hyperuricemia. Rheumatology 2010;49:1929-34
46. Cook S, Hugli O, Egli M, et al. Clustering of cardiovascular risk factors mimicking the human MS. Swiss Med Wkly 2003;133:360-3
47. Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced MS. Am J Physiol Renal Physiol 2008;294:F710-18
48. Tsouli SG, Liberopoulos EM, Mikhailidis DP, et al. Elevated UA levels in MS: an active component or an innocent bystander? Metab Clin Exp 2006;55:1293-301
49. Fang J, Alderman MH. Serum UA and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-10
50. Niskanen LK, Laaksonen DE, Nyyssonen K, et al. UA level as a risk for cardiovascular and all-mortality in middle-age men: a prospective cohort study. Arch Intern Med 2004;164:1546-51
51. Williams IL, Wheatcroft SB, Shah AM, Kearney MT. Obesity, atherosclerosis and the vascular endothelium: mechanism of reduced nitric oxide bioavailability in obese human. Int J Obes 2002;26:754-64
52. Asl SZ, Ghasemi A, Azizi F. Serum nitric oxide metabolites in subjects with MS. Clin Biochem 2008;41:1342-7
53. Forstemann U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem 2006;387:1521-33
54. Johnson RJ, Herrera-Acosta J, Screiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt sensitive hypertension. N Engl J Med 2002;346:913-23
55. Johnson RJ, Rodriguez-Iturbe B, Kang D-H, et al. A unifying pathway for essential hypertension. Am J Hypertens 2005;18:431-40
56. Sekine T, Miyazaki H, Endou H. Molecular physiology of renal organic anion transporter. Am J Physiol Renal Physiol 2006;290:F251-61
57. Onat H, Uyarel H, Hergenc G, et al. Serum acid is a determinant of MS in a population-based study. Am J Hypertens 2006;19:1055-62
58. Ford ES, Li C, Cook S, Choi HK. Serum concentrations of UA and the MS among US children and adolescents. Circulation 2007;115:2526-32
59. Bedir A, Topbas M, Tanyeri F, et al. Leptin might be a regulator of serum UA concentration in humans. Jpn Heart J 2005;44:527-36
60. Lin JD, Chiou WK, Chang HY, et al. Serum UA and leptin levels in MS: a quandary over the role of UA. Metabolism 2007;56:751-6
61. FOX IH. Metabolic basis for disorders of purine nucleotide degradation. Metabolism 1981;30:616-34
62. Sui X, Church TS, Meriwether RA, et al. UA and the development of MS in women and men. Metabolism 2008;57:845-52
63. Heinig M, Johnson RJ. Role of UA in hypertension, renal disease, an MS. Cleve Clin J Med 2006;73:1059-64
64. Muscelli E, Natali A, Bianchi S, et al. Effect of insulin on renal sodium and UA handling in essential hypertension. Am J Hypertens 1996;9:746-52
65. Lin SD, Tsai DH, Hsu SR. Association between serum UA level and components of the MS. J Chin Med Assoc 2006;69:512-16
66. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 1998;57:509-10
67. Tinahones JF, Perez-Lindon G, Soriguer FJ, et al. Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperurecemic-hypertriglyceridemic patients. J Clin Endocrinol Metab 1997;82:1188-91
68. Vourinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and IR. J Clin Endocrinol Metab 1994;78:25-9
69. Clausen JO, Borch-Johnsen, K, Ibsen H, Pedersen O. Analysis of the relationship between fasting serum UA and the insulin sensitivity index in a population-basedsample of 380 young healthy Caucasians. Eur J Endocrinol 1998;138:63-9
70. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the IR syndrome. The IR Atherosclerosis Study (IRAS). Circulation 2000;102:42-7
71. Haffner SM. IR, inflammation and the prediabetic state. Am J Cardiol 2003;92:18-26J
72. Tamakoshi K, Yatsuya H, Kondo T, et al. The MS is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 2003;27:443-9
73. Santos AC, Lopes C, Guimaraes JT, Barros H. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in MS. Intern J Obes 2005;29:1452-6
74. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of the white adipose tissue. Br J Nutr 2004;92:347-55
75. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of mielomonocytic progenitors and the functions of the macrophages. Blood 2000;96:1723-32
76. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-6
77. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-301
78. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progress to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-33
79. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and IL-6 expression in human obesity and IR. Am J Physiol Endocrinol Metab 2001;280:E745-51
80. Maeda N, Takahashi M, Funahashi Y, et al. PPAR-gamma ligands increase expression and plasma concentration of adiponectin, an adipose-driven protein. Diabetes 2001;50:2094-9
81. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Artherioscler Thromb Vasc Biol 2000;20:1595-9
82. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004;43:1318-23
83. Santaniemi M, Kesaniemi YA, Ukkola O. Low plasma adiponectin concentration is an indicator of the MS. Eur J Endocr 2006;155:745-50
84. Waring WS, Webb DJ, Maxwell SRJ. UA as a risk factor for cardiovascular disease. Q J Med 2000;93:707-13
85. Baldwin W, McRae S, Marek G, et al. Hyperuricemia is a mediator of the proinflammatory imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011;60:1258-69
86. Simao ANC, Lozovoy MAB, Simao TNC, et al. Adiponectinemia is associated with uricemia but not with proinflammatory status in women with MS. J Nutr Metab 2012;2012: In press
87. Patel DA, Srinivasan SR, Xu JH, et al. Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study. Metab Clin Exp 2006;55:1551-7
88. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002;29:1350-5
89. Savage PJ, Pressel SL, Curb JD, et al. Influence of long term, low dose, diuretic-based, antihypertensive therapy on glucose, lipid UA, and potassium levels in older men and women with isolated systolic hypertension: the systolic hypertension in the elderly program. Arch Intern Med 1998;158:741-51
90. Tsouli SG, Liberopoulos EM, Kiortsis DN, et al. Combined treatment with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence. J Cardiovasc Pharmacol Ther 2006;11:1-15
91. Alderman M, Aiyer KJ. UA: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20:369-79
92. Sennesael JJ, Lamote JG, Violet I, et al. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine treated renal allograft recipients. Am J Kidney 1996;27:701-8
93. Liamis G, Bairaktari ET, Elisaf MS. Effect of fenofibrate on serum UA levels. Am J Kidney Dis 1999;34:594
94. Milionis HJ, Kakafika AL, Tsouli SG, et al. Effects of statin treatment in UA homeostasis in patients with primary hyperlipidemia. Am Heart J 2004;148:635-40
95. Youssef F, Gupta P, Seifalian AM, et al. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004;55:53-62
96. Fruehwald-Schultes B, Oltmanns KM, Toschek B, et al. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight health men. Metabolism 2002;51:531-6
97. Tetradze L, Virsaladze D, Javashvili L, et al. Relation of serum UA levels with basic metabolic parameters in patients with MS during insulin-sensitizing therapy. Georgian Med News 2007;151:44-7
98. Barskova VG, Eliseev MS, Nasonov EL, et al. Use of metformin (siofor) in patients with gout and IR (pilot 6-month results). Ter Arkh 2005;77(12):44-9
99. Filippatos TD, Kiortsis DN, Liberopoulos EM, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005;21:457-68
100. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005;31:15-22
101. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and UA handling in elderly patients. Arthritis Rheum 2000;43-103-8
102. Louthrenoo W, Kasitanon N, Wichainun R, et al. Effects of minidose aspirinon renal function and renal UA handling in healthy young adults. J Clin Rheumatol 2002;8:299-304
103. Wortmann R.L. Gout and hyperuricemia. Curr. Opin. Rheumatol 2002;14:281-6
104. Yiginer O, Ozcelik F, Inanc T, et al. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in MS. Clin Res Cardiol 2008;97:334-40